$2.47
+0.09 (+3.78%)
Open$2.38
Previous Close$2.38
Day High$2.48
Day Low$2.25
52W High$2.95
52W Low$0.71
Volume—
Avg Volume5.07M
Market Cap166.64M
P/E Ratio—
EPS$-0.61
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+142.9% upside
Current
$2.47
$2.47
Target
$6.00
$6.00
$4.29
$6.00 avg
$7.91
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 27.0K | 9.23M | 9.01M |
| Net Income | -45,753,804 | -678,125 | -522,642 |
| Profit Margin | -155,587.4% | -7.4% | -5.8% |
| EBITDA | -42,279,430 | -963,511 | -904,753 |
| Free Cash Flow | — | -508,030 | -465,093 |
| Rev Growth | — | +6.0% | +24.9% |
| Debt/Equity | 0.02 | 0.23 | 0.22 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |